Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × ponatinib × Myeloid × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 17 Observational 5 Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

nilotinib 3 ruxolitinib 2 venetoclax 1 selinexor 1 ponatinib 1 navitoclax 1 midostaurin 1 fludarabine phosphate 1 asciminib 1 Whole-Body Irradiation 1 Tacrolimus 1 Mycophenolic Acid 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Busulfan 1 Bone Marrow Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01592136 2018-02-06

Expanded Access Program of Ponatinib

Takeda

Approved for marketing

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡